A. B. Ferhanoğlu Et Al. , " Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience," 2017 ASH , California, United States Of America, 2017
Ferhanoğlu, A. B. Et Al. 2017. Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience. 2017 ASH , (California, United States Of America).
Ferhanoğlu, A. B., Özbalak, M. M., Salihoğlu, A., Soysal, T., Karadoğan, I., Paydaş, S., ... Özdemir, E.(2017). Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience . 2017 ASH, California, United States Of America
Ferhanoğlu, Ahmet Et Al. " Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience," 2017 ASH, California, United States Of America, 2017
Ferhanoğlu, Ahmet B. Et Al. " Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience." 2017 ASH , California, United States Of America, 2017
Ferhanoğlu, A. B. Et Al. (2017) . " Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience." 2017 ASH , California, United States Of America.
@conferencepaper{conferencepaper, author={Ahmet Burhan Ferhanoğlu Et Al. }, title={ Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience}, congress name={2017 ASH}, city={California}, country={United States Of America}, year={2017}}